Effectiveness of Vortioxetine for the Treatment of Emotional Blunting in Patients with Major Depressive Disorder Experiencing Inadequate Response to SSRI/SNRI Monotherapy in Spain: Results from the COMPLETE Study

References

• World Health Organization. Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: World Health Organization; 2017. Available from: https://apps.who.int/iris/bitstream/handle/10665/254610/WHO-MSD-MER-2017.2-eng.pdf. Accessed February 22, 2023.
   Google Scholar
• Vieta E, Alonso J, Pérez-Sola V, et al. Epidemiology and costs of depressive disorder in Spain: the EPICO study. Eur Neuropsychopharm. 2021;50:93–103. doi:10.1016/j.euroneuro.2021.04.022
   PubMedGoogle Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917. doi:10.1176/ajp.2006.163.11.1905
   PubMed Web of Science ®Google Scholar
• Price J, Cole V, Goodwin GM. Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study. Br J Psychiatry. 2009;195(3):211–217. doi:10.1192/bjp.bp.108.051110
   PubMed Web of Science ®Google Scholar
• Sansone RA, Sansone LA. SSRI-induced indifference. Psychiatry. 2010;7(10):14–18.
   Google Scholar
• Read J, Cartwright C, Gibson K. Adverse emotional and interpersonal effects reported by 1829 New Zealanders while taking antidepressants. Psychiatry Res. 2014;216(1):67–73. doi:10.1016/j.psychres.2014.01.042
   PubMed Web of Science ®Google Scholar
• Goodwin GM, Price J, De Bodinat C, Laredo J. Emotional blunting with antidepressant treatments: a survey among depressed patients. J Affect Disord. 2017;221:31–35. doi:10.1016/j.jad.2017.05.048
   PubMed Web of Science ®Google Scholar
• Read J, Williams J. Adverse effects of antidepressants reported by a large international cohort: emotional blunting, suicidality, and withdrawal effects. Curr Drug Saf. 2018;13(3):176–186. doi:10.2174/1574886313666180605095130
   PubMed Web of Science ®Google Scholar
• Marazziti D, Mucci F, Tripodi B, et al. Emotional blunting, cognitive impairment, bone fractures, and bleeding as possible side effects of long-term use of SSRIs. Clin Neuropsychiatry. 2019;16(2):75–85.
   PubMed Web of Science ®Google Scholar
• Padala PR, Padala KP, Majagi AS, Garner KK, Dennis RA, Sullivan DH. Selective serotonin reuptake inhibitors-associated apathy syndrome: a cross sectional study. Medicine. 2020;99(33):e21497. doi:10.1097/MD.0000000000021497
   PubMedGoogle Scholar
• Christensen MC, Ren H, Fagiolini A. Emotional blunting in patients with depression. Part I: clinical characteristics. Ann Gen Psychiatry. 2022;21(1):10. doi:10.1186/s12991-022-00387-1
   PubMed Web of Science ®Google Scholar
• Masdrakis VG, Markianos M, Baldwin DS. Apathy associated with antidepressant drugs: a systematic review. Acta Neuropsychiatr. 2023;35(4):189–204. doi:10.1017/neu.2023.6
   PubMedGoogle Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed., text revision. Washington, DC: American Psychiatric Association; 2022.
   Google Scholar
• Sandell K, Bornäs H. Functioning numbness instead of feelings as a direction: young adults’ experiences of antidepressant use. Sociology. 2017;51(3):543–558. doi:10.1177/0038038515591947
   Google Scholar
• Christensen MC, Ren H, Fagiolini A. Emotional blunting in patients with depression. Part II: relationship with functioning, well-being, and quality of life. Ann Gen Psychiatry. 2022;21(1):20. doi:10.1186/s12991-022-00392-4
   PubMed Web of Science ®Google Scholar
• Rosenblat JD, Simon GE, Sachs GS, et al. Treatment effectiveness and tolerability outcomes that are most important to individuals with bipolar and unipolar depression. J Affect Disord. 2019;243:116–120. doi:10.1016/j.jad.2018.09.027
   PubMed Web of Science ®Google Scholar
• Fagiolini A, Florea I, Loft H, Christensen MC. Effectiveness of vortioxetine on emotional blunting in patients with major depressive disorder with inadequate response to SSRI/SNRI treatment. J Affect Disord. 2021;283:472–479. doi:10.1016/j.jad.2020.11.106
   PubMed Web of Science ®Google Scholar
• Thase ME, Mahableshwarkar AR, Dragheim M, Loft H, Vieta E. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. Eur Neuropsychopharmacol. 2016;26(6):979–993. doi:10.1016/j.euroneuro.2016.03.007
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Florea I, Jacobsen PL, Zhong W, Nomikos GG. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms. J Affect Disord. 2016;206:140–150. doi:10.1016/j.jad.2016.07.015
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Harrison J, Loft H, Jacobson W, Olsen CK. The effects of vortioxetine on cognitive function in patients with major depressive disorder: a meta-analysis of three randomized controlled trials. Int J Neuropsychopharmacol. 2016;19(10):pyw055. doi:10.1093/ijnp/pyw055
   PubMed Web of Science ®Google Scholar
• Florea I, Loft H, Danchenko N, et al. The effect of vortioxetine on overall patient functioning in patients with major depressive disorder. Brain Behav. 2017;7(3):e00622. doi:10.1002/brb3.622
   PubMed Web of Science ®Google Scholar
• Christensen MC, Florea I, Lindsten A, Baldwin DS. Efficacy of vortioxetine on the physical symptoms of major depressive disorder. J Psychopharmacol. 2018;32(10):1086–1097. doi:10.1177/0269881118788826
   PubMed Web of Science ®Google Scholar
• Iovieno N, Papakostas GI, Feeney A, et al. Vortioxetine versus placebo for major depressive disorder: a comprehensive analysis of the clinical trial dataset. J Clin Psychiatry. 2021;82(4):20r13682. doi:10.4088/JCP.20r13682
   PubMed Web of Science ®Google Scholar
• Adair M, Christensen MC, Florea I, Loft H, Fagiolini A. Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: an updated analysis of efficacy and tolerability. J Affect Disord. 2023;328:345–354. doi:10.1016/j.jad.2023.01.074
   PubMed Web of Science ®Google Scholar
• Christensen MC, McIntyre RS, Florea I, Loft H, Fagiolini A. Vortioxetine 20 mg/day in patients with major depressive disorder: updated analysis of efficacy, safety, and optimal timing of dose adjustment. CNS Spectr. 2023;28(1):90–97. doi:10.1017/S1092852921000936
   PubMed Web of Science ®Google Scholar
• Christensen MC, McIntyre RS, Adair M, Florea I, Loft H, Fagiolini A. Clinical benefits of vortioxetine 20 mg/day in patients with major depressive disorder. CNS Spectr. 2023;28(6):693–701. doi:10.1017/S1092852923002249
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Loft H, Christensen MC. Efficacy of vortioxetine on anhedonia: results from a pooled analysis of short-term studies in patients with major depressive disorder. Neuropsychiatr Dis Treat. 2021;17:575–585. doi:10.2147/NDT.S296451
   PubMed Web of Science ®Google Scholar
• Price J, Cole V, Doll H, Goodwin GM. The Oxford Questionnaire on the Emotional Side-effects of Antidepressants (OQuESA): development, validity, reliability and sensitivity to change. J Affect Disord. 2012;140(1):66–74. doi:10.1016/j.jad.2012.01.030
   PubMed Web of Science ®Google Scholar
• Christensen MC, Fagiolini A, Florea I, Loft H, Cuomo A, Goodwin GM. Validation of the Oxford Depression Questionnaire: sensitivity to change, minimal clinically important difference, and response threshold for the assessment of emotional blunting. J Affect Disord. 2021;294:924–931. doi:10.1016/j.jad.2021.07.099
   PubMed Web of Science ®Google Scholar
• Cao B, Park C, Subramaniapillai M, et al. The efficacy of vortioxetine on anhedonia in patients with major depressive disorder. Front Psychiatry. 2019;10:17. doi:10.3389/fpsyt.2019.00017
   PubMed Web of Science ®Google Scholar
• Fehnel SE, Bann CM, Hogue SL, Kwong WJ, Mahajan SS. The development and psychometric evaluation of the Motivation and Energy Inventory (MEI). Qual Life Res. 2004;13(7):1321–1336. doi:10.1023/B:QURE.0000037502.64077.4d
   PubMed Web of Science ®Google Scholar
• Christensen MC, Adair M, Loft H, McIntyre RS. The Motivation and Energy Inventory (MEI): analysis of the clinically relevant response threshold in patients with major depressive disorder and emotional blunting using data from the COMPLETE study. J Affect Disord. 2023;323:547–553. doi:10.1016/j.jad.2022.11.033
   PubMedGoogle Scholar
• Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996;11(Suppl 3):89–95. doi:10.1097/00004850-199606003-00015
   PubMed Web of Science ®Google Scholar
• Sheehan KH, Sheehan DV. Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol. 2008;23(2):70–83. doi:10.1097/YIC.0b013e3282f2b4d6
   PubMed Web of Science ®Google Scholar
• Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998;44:77–87. doi:10.1016/S0006-3223(98)00126-7
   PubMed Web of Science ®Google Scholar
• Wichniak A, Wierzbicka A, Walęcka M, Jernajczyk W. Effects of antidepressants on sleep. Curr Psychiatry Rep. 2017;19(9):63. doi:10.1007/s11920-017-0816-4
   PubMed Web of Science ®Google Scholar
• Zhou S, Li P, Lv X, et al. Adverse effects of 21 antidepressants on sleep during acute-phase treatment in major depressive disorder: a systemic review and dose-effect network meta-analysis. Sleep. 2023;46(10):zsad177. doi:10.1093/sleep/zsad177
   PubMedGoogle Scholar
• Golder S, Medaglio D, O’Connor K, Hennessy S, Gross R, Gonzalez Hernandez G. Reasons for discontinuation or change of selective serotonin reuptake inhibitors in online drug reviews. JAMA Netw Open. 2023;6(7):e2323746. doi:10.1001/jamanetworkopen.2023.23746
   PubMedGoogle Scholar
• Baldwin DS, Chrones L, Florea I, et al. The safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol. 2016;30(3):242–252. doi:10.1177/0269881116628440
   PubMed Web of Science ®Google Scholar
• Cao B, Park C, Rosenblat JD, et al. Changes in sleep predict changes in depressive symptoms in depressed subjects receiving vortioxetine: an open-label clinical trial. J Psychopharmacol. 2019;33(11):1388–1394. doi:10.1177/0269881119874485
   PubMed Web of Science ®Google Scholar
• Liguori C, Ferini-Strambi L, Izzi F, et al. Preliminary evidence that vortioxetine may improve sleep quality in depressed patients with insomnia: a retrospective questionnaire analysis. Br J Clin Pharmacol. 2019;85(1):240–244. doi:10.1111/bcp.13772
   PubMed Web of Science ®Google Scholar
• Clayton AH, El Haddad S, Iluonakhamhe JP, Ponce Martinez C, Schuck AE. Sexual dysfunction associated with major depressive disorder and antidepressant treatment. Expert Opin Drug Saf. 2014;13(10):1361–1374. doi:10.1517/14740338.2014.951324
   PubMed Web of Science ®Google Scholar
• Cartwright C, Gibson K, Read J, Cowan O, Dehar T. Long-term antidepressant use: patient perspectives of benefits and adverse effects. Patient Prefer Adherence. 2016;10:1401–1407. doi:10.2147/PPA.S110632
   PubMed Web of Science ®Google Scholar
• Atmaca M. Selective serotonin reuptake inhibitor-induced sexual dysfunction: current management perspectives. Neuropsychiatr Dis Treat. 2020;16:1043–1050. doi:10.2147/NDT.S185757
   PubMed Web of Science ®Google Scholar
• Jacobsen PL, Mahableshwarkar AR, Palo WA, Chen Y, Dragheim M, Clayton AH. Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis. CNS Spectr. 2016;21(5):367–378. doi:10.1017/S1092852915000553
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Florea I, Pedersen MM, Christensen MC. Head-to-head comparison of vortioxetine versus desvenlafaxine in patients with major depressive disorder with partial response to SSRI therapy: results of the VIVRE study. J Clin Psychiatry. 2023;84(4):23m14780. doi:10.4088/JCP.23m14780
   PubMed Web of Science ®Google Scholar
• Jacobsen PL, Mahableshwarkar AR, Chen Y, Chrones L, Clayton AH. Effect of vortioxetine vs. escitalopram on sexual functioning in adults with well-treated major depressive disorder experiencing SSRI-induced sexual dysfunction. J Sex Med. 2015;12(10):2036–2048. doi:10.1111/jsm.12980
   PubMed Web of Science ®Google Scholar
• Jacobsen PL, Nomikos GG, Zhong W, Cutler AI, Affinito H, Clayton A. Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram. CNS Spectr. 2020;25(1):50–63. doi:10.1017/S1092852919000750
   PubMed Web of Science ®Google Scholar
• Montejo AL, Sánchez-Sánchez F, De Alarcón R, et al. Switching to vortioxetine in patients with poorly tolerated antidepressant-related sexual dysfunction in clinical practice: a 3-month prospective real-life study. J Clin Med. 2024;13(2):546. doi:10.3390/jcm13020546
   PubMedGoogle Scholar
• Subramaniapillai M, Mansur RB, Zuckerman H, et al. Association between cognitive function and performance on effort based decision making in patients with major depressive disorder treated with vortioxetine. Compr Psychiatry. 2019;94:152113. doi:10.1016/j.comppsych.2019.07.006
   PubMed Web of Science ®Google Scholar
• Mattingly GW, Necking O, Schmidt SN, Reines E, Ren H. Long-term safety and efficacy, including anhedonia, of vortioxetine for major depressive disorder: findings from two open-label studies. Curr Med Res Opin. 2023;39(4):613–619. doi:10.1080/03007995.2023.2178082
   PubMed Web of Science ®Google Scholar
• IsHak WW, Greenberg JM, Cohen RM. Predicting relapse in major depressive disorder using patient-reported outcomes of depressive symptom severity, functioning, and quality of life in the Individual Burden of Illness Index for Depression (IBI-D). J Affect Disord. 2013;151(1):59–65. doi:10.1016/j.jad.2013.05.048
   PubMed Web of Science ®Google Scholar
• IsHak WW, James DM, Mirocha J, et al. Patient-reported functioning in major depressive disorder. Ther Adv Chronic Dis. 2016;7(3):160–169. doi:10.1177/2040622316639769
   PubMed Web of Science ®Google Scholar
• Papalexi E, Galanopoulos A, Roukas D, et al. Residual cognitive and psychosocial functional impairment in outpatients in Greece who responded to conventional antidepressant monotherapy treatments for major depressive disorder (MDD). J Affect Disord. 2022;314:185–192. doi:10.1016/j.jad.2022.07.009
   PubMed Web of Science ®Google Scholar
• Lam RW, McIntosh D, Wang J, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 1. Disease burden and principles of care. Can J Psychiatry. 2016;61:510–523. doi:10.1177/0706743716659416
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Nakagome K, Asami Y, Pappadopulos EA, Boucher M. Restoring function in major depressive disorder: a systematic review. J Affect Disord. 2017;215:299–313. doi:10.1016/j.jad.2017.02.029
   PubMed Web of Science ®Google Scholar
• Yang H, Gao S, Li J, et al. Remission of symptoms is not equal to functional recovery: psychosocial functioning impairment in major depression. Front Psychiatry. 2022;13:915689. doi:10.3389/fpsyt.2022.915689
   PubMed Web of Science ®Google Scholar
• Cao B, Zhu J, Zuckerman H, et al. Pharmacological interventions targeting anhedonia in patients with major depressive disorder: a systematic review. Prog Neuropsychopharmacol Biol Psychiatry. 2019;92:109–117. doi:10.1016/j.pnpbp.2019.01.002
   PubMed Web of Science ®Google Scholar
• Pan Z, Rosenblat JD, Swardfager W, McIntyre RS. Role of proinflammatory cytokines in dopaminergic system disturbances, implications for anhedonic features of MDD. Curr Pharm Des. 2017;23(14):2065–2072. doi:10.2174/1381612823666170111144340
   PubMedGoogle Scholar
• Höflich A, Michenthaler P, Kasper S, Lanzenberger R. Circuit mechanisms of reward, anhedonia, and depression. Int J Neuropsychopharmacol. 2019;22(2):105–118. doi:10.1093/ijnp/pyy081
   PubMed Web of Science ®Google Scholar
• Nutt D, Demyttenaere K, Janka Z, et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol. 2007;21(5):461–471. doi:10.1177/0269881106069938
   PubMed Web of Science ®Google Scholar
• De Diego-Adeliño J, Crespo JM, Mora F, et al. Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review. Exp Opin Drug Saf. 2022;21(5):673–690. doi:10.1080/14740338.2022.2019705
   PubMedGoogle Scholar
• Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther. 2015;145:43–57. doi:10.1016/j.pharmthera.2014.07.001
   PubMed Web of Science ®Google Scholar
• Bang-Andersen B, Ruhland T, Jørgensen M, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011;54:3206–3221. doi:10.1021/jm101459g
   PubMed Web of Science ®Google Scholar
• Mørk A, Pehrson A, Brennum LT, et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther. 2021;340:666–675. doi:10.1124/jpet.111.189068
   Google Scholar
• Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): actions at serotonin receptors may enhance downstream release of four pro-cognitive neurotransmitters. CNS Spectr. 2015;20(6):515–519. doi:10.1017/S1092852915000358
   PubMedGoogle Scholar
• Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): modifying serotonin’s downstream effects on glutamate and GABA (gamma amino butyric acid) release. CNS Spectr. 2015;20(4):331–336. doi:10.1017/S1092852915000334
   PubMed Web of Science ®Google Scholar
• Wilson S, Højer AM, Buchberg J, Areberg J, Nutt DJ. Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men. J Psychopharmacol. 2015;29(10):1085–1091. doi:10.1177/0269881115599387
   PubMedGoogle Scholar
• Leiser SC, Iglesias-Bregna D, Westrich L, Pehrson AL, Sanchez C. Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: part 2, pharmacological interactions in rodents suggest a role of serotonin-3 receptor antagonism. J Psychopharmacol. 2015;29(10):1092–1105. doi:10.1177/0269881115592347
   PubMed Web of Science ®Google Scholar